Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 11/19/25 → 11/19/27 |
Financiación
- Bristol Myers Squibb Company: 27.500,00 US$
25-LUN-145-BMS CA240-0029 A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTA
- Villano, PhD, John (PI)